Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer 

Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy
Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer  ( Dr Filippo Pietrantonio - ‎The National Cancer Institute of Milan, Milan, Italy )
23 Oct 2023

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer

Dr Aditya Bardia - Mass General Cancer Center, Boston, USA
Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )
23 Oct 2023

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer

Prof Thomas Powles - Barts Cancer Centre, London, UK
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer ( Prof Thomas Powles - Barts Cancer Centre, London, UK )
22 Oct 2023

Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
22 Oct 2023

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC ( Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira )
22 Oct 2023

Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC

Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA
Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )
21 Oct 2023

Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer

Dr Julien Hadoux - Institut Gustave Roussy, Villejuif, France
Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer ( Dr Julien Hadoux - Institut Gustave Roussy, Villejuif, France )
21 Oct 2023

Cost-benefit analysis of new cancer medicines: The difficult choices of governments

Dr Nwamaka Lasebikan, Prof P.G. Roy, Dr Didier Verhoeven
Cost-benefit analysis of new cancer medicines: The difficult choices of governments ( Dr Nwamaka Lasebikan, Prof P.G. Roy, Dr Didier Verhoeven )
8 Oct 2023

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )
3 Oct 2023

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer

Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA
Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer ( Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA )
21 Sep 2023

OncoAlert Round Up for September 1-7, 2023

Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for September 1-7, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
12 Sep 2023

Part 6: Which different PARP inhibitors are available

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK
Part 6: Which different PARP inhibitors are available ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )
5 Sep 2023